Alzheimer's disease (AD), is a multifactorial neurodegenerative disorder characterized by memory loss and cognitive deficit. Various drug targets implicated in AD are β-amyloid (Aβ) peptides, cholinesterase enzymes, and free radicals. Plants derived phytoconstituents provides a vast pool of diverse compounds as a source of novel drugs. In view of this, the Elettaria cardamomum L. Maton. extract and its active phytoconstituents alpha-terpinyl acetate were used to study the disease-modifying effects in AD. The present study successfully demonstrated for the first time the therapeutic potential of alpha-terpinyl acetate as it binds to multiple drug targets, resulting in inhibition of acetylcholinesterase (AChE) enzyme, butyrylcholinesterase (BuChE) enzyme, reduced Aβ induced neurotoxicity, reduced hydrogen peroxide induced oxidative stress, antioxidant capacity, and anti-amyloidogenic property. In conclusion, alpha-terpinyl acetate can be used as a suitable lead to develop a molecule that might have multi-targeted directed ligand (MTDL) potential and disease amelioration effects in AD.

阿尔茨海默氏病（AD）是一种以记忆力减退和认知缺陷为特征的多因素神经退行性疾病。与AD有关的各种药物靶标是β-淀粉样蛋白（Aβ）肽，胆碱酯酶和自由基。植物衍生的植物成分提供了大量的各种化合物作为新药的来源。鉴于此，Elettaria小豆蔻莫顿 提取物及其活性植物成分醋酸α-萜品基酯被用于研究AD中的疾病缓解作用。本研究首次成功证明了乙酸α-叔丁基乙酸酯与多种药物靶标结合的治疗潜力，从而抑制了乙酰胆碱酯酶（AChE），丁酰胆碱酯酶（BuChE）酶，减少了Aβ诱导的神经毒性，减少了过氧化氢氧化应激，抗氧化能力和抗淀粉样变性。总之，乙酸α-叔戊酯可以用作开发可能在AD中具有多靶点定向配体（MTDL）潜力和疾病改善作用的分子的合适先导。